Registered Outsourcing Facilities

Facilities Registered As Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act)

Updated as of 8/28/15

Information Concerning Outsourcing Facility Registration

This table lists the outsourcing facilities that have submitted registration information that has been determined to be complete by the data lock date for the latest weekly update of the table. 

Facility NameInitial Date of Registration as an Outsourcing Facility1Date of Most Recent Registration as an Outsourcing Facility1End Date of Last FDA Inspection Related to Compounding2Was a Form FDA-483 issued?3Other FDA Action, if Any, Based on Last Inspection4,5Intends to Compounds Sterile Drugs From Bulk Drug Substances6
ACS Dobfar Info S.A., Campascio, Switzerland1/9/20151/9/2015Not yet inspectedN/AN/AYes
Advanced Pharma, Inc., Houston, TX
Alexander Infusion LLC dba Avanti Health Care, New Hyde Park, NY4/21/20141/7/20157/9/2014YesWarning Letter - 3/27/2015Yes
AnazaoHealth Corporation, Las Vegas, NV9/23/201412/29/20141/30/2015YesOpenYes
Avella Specialty Pharmacy, Phoenix, AZ2/24/20141/20/20157/31/2015YesOpen7No
Banner Health, Chandler, AZ12/26/20131/27/20153/20/2015YesOpenNo
Brookfield Medical/Surgical Supply, Inc., Brookfield, CT1/12/20151/12/20154/9/2015YesOpenYes
California Pharmacy and Compounding Center, Newport Beach, CA4/30/201411/24/2014




Warning Letter - 6/17/2015Yes
Cantrell Drug Company, Little Rock, AR12/16/201312/30/201411/4/2013YesWarning Letter - 1/21/2015Yes
Central Admixture Pharmacy Services, Inc., Allentown, PA2/28/201412/15/20142/11/2015YesOpen7Yes
Central Admixture Pharmacy Services, Inc., San Diego, CA
Coastal Meds LLC, Biloxi, MS12/23/201412/23/201411/10/2014YesOpenYes
Complete Pharmacy and Medical Systems, Miami Lakes, FL6/6/20141/13/20158/12/2014YesOpenYes
Delta Pharma, Inc., Ripley, MS8/6/20143/10/201510/2/2013YesWarning Letter - 12/9/2014Yes
Downing Labs, LLC, Dallas, TX6/23/20156/23/20157/16/2014YesFDA - Requested Recall Letter - 9/9/2014 7Yes
Eagle Pharmacy, Inc., Birmingham, AL6/16/20156/16/20158/21/2015YesOpenYes
Edge Pharmacy Services, LLC, Colchester, VT1/21/20141/15/20158/20/2014YesOpenYes
Exela Pharma Sciences, LLC, Lenoir, NC6/6/20141/5/201511/21/2014YesOpenYes

Healix Infusion Therapy, Inc., Sugar Land, TX

Hybrid Pharma, LLC, Deerfield Beach, FL1/14/20151/14/2015Not yet inspectedN/AN/AYes
ILS Genomics, LLC Morrisville, NC8/7/2015 8/7/2015 Not yet inspected N/A N/A No 
INCELL Corp., LLC, San Antonio, TX  5/29/2015 5/29/2015 Not yet inspected N/A N/A Yes 
Infusion Options Inc., Brooklyn, NY1/24/201412/23/20144/23/2014YesOpenNo
Isomeric Pharmacy Solutions, LLC, Salt Lake City, UT7/14/20157/14/2015Not yet inspectedN/AN/AYes
JCB Laboratories, North Wichita, KS
1/21/201411/25/20142/27/2013YesWarning Letter - 7/7/2014Yes
Jubilant HollisterStier LLC, Spokane, WA6/3/20142/13/201512/02/2014YesOpenYes
Kings Park Slope, Inc., Brooklyn, NY12/23/20131/5/20153/14/2014YesWarning Letter - 3/27/2015Yes
KRS Global Biotechnology, Inc., Boca Raton, FL12/15/20131/7/20153/17/2014YesWarning Letter - 7/6/2015Yes
LeeSar, Inc., Fort Myers, FL4/30/20141/30/20158/8/2014YesOpenNo
Leiter's Compounding, 17 Great Oaks Blvd., San Jose, CA1/31/20141/26/201510/7/2014YesOpenYes
Medi-Fare Drug, Blacksburg, SC12/17/201312/31/20149/12/2014YesOpen7Yes
Medistat RX, LLC, Foley, AL11/21/201411/21/20149/18/2014YesOpenYes
Nephron Sterile Compounding Center, LLC (NSCC), West Columbia, SC7/15/201412/29/2014Not yet inspectedN/AN/AYes
OPS International Inc., Olympia Pharmacy, Orlando, FL3/10/20141/27/201512/4/2014YesOpen7Yes
Pharmaceutic Labs, LLC, Albany, NY3/10/20141/28/2015Not yet inspectedN/AN/AYes
Pharmakon Pharmaceuticals, Noblesville, IN1/23/201412/2/20143/13/2014; 4/8/2014


(3/13/2014) and (4/8/2014)

Warning Letter - 5/21/15No
Pharmalogic CSP, Bridgeport, WV7/1/20141/5/201512/12/2014YesOpenYes
Pharm D Solutions, LLC, Houston, TX8/6/20143/24/20156/5/2015YesOpenYes
PharMedium Services, LLC, Cleveland, MS
PharMedium Services, LLC, Edison, NJ
PharMedium Services, LLC, Memphis, TN12/11/201311/24/20147/10/2015
PharMedium Services, LLC, Sugar Land, TX
Warning Letter - 7/18/2014No
Pine Pharmaceuticals, LLC, Tonawanda, NY6/17/201412/29/201410/16/2014NoNoYes
Pinnacle Compounding Pharmacy, Las Vegas, NV7/10/20157/10/20157/31/2015YesOpenYes
Premier Pharmacy Labs Inc., Weeki Wachee, FL4/16/201412/18/20145/9/2014YesWarning Letter - 4/27/2015Yes
Qualgen LLC, formerly registered as Amerilab LLC, Edmond, OK5/23/20145/8/2015Not yet inspectedN/AN/AYes
Region Care, Inc., Great Neck, NY12/24/20131/7/20153/20/2014YesWarning Letter - 4/8/2015Yes
RXQ Compounding LLC, Athens, OH1/2/20151/2/2015Not yet inspectedN/AN/AYes
SCA Pharmaceuticals, Little Rock, AR
YesWarning Letter - 6/25/2015Yes
SSM St. Clare Health Center, Fenton, MO2/18/20141/5/20158/14/2014YesOpenNo
STERRX, LLC, Plattsburgh, NY  5/29/2015 5/29/2015 Not yet inspected N/A N/A Yes 
Triangle Compounding Pharmacy Inc., Cary, NC



Yes (9/22/2014 and 1/16/2015)Open7Yes
Unique Pharmaceuticals, Ltd., Temple TX1/17/201411/25/2014



US Compounding, Inc., Conway, AR12/20/201312/24/20148/21/2015YesOpen7Yes
US Specialty Formulations LLC, Bethlehem, PA


1.       The "initial date of registration as an outsourcing facility" is the date the facility was first registered (i.e., the date FDA determined that the initial registration information submitted for the facility was complete, and for firms first registering onor after October 1, 2014, the establishment fee was paid in full).

Under section 503B(b) of the FD&C Act, after the initial registration, a facility that elects to continue to be registered with FDA as an outsourcing facility must re-register annually. Beginning in fiscal year (FY) 2015 (October 1, 2014 to September 30, 2015), a facility that elects to register (or re-register) with FDA as an outsourcing facility must pay an annual establishment fee. The “date of most recent registration as an outsourcing facility” reflects the date FDA determined the most recently submitted registration information was complete and the annual establishment fee for that fiscal year paid in full. 

Unless a previously registered outsourcing facility re-registers and pays the annual establishment fee in full during the registration period (between October 1 and December 31 of each calendar year), the facility will be removed from the list of registered outsourcing facilities on January 1 of the next calendar year. 

2.       Inspections identified in this table are associated with the facility at the listed address. A company may own or operate more than one registered outsourcing facility. FDA’s web page Compounding: Inspections, Recalls, and Other Actions may contain information about compounding facilities under the same ownership as the listed registered outsourcing facility.

Inspections may take place over several days, weeks, or longer. The date of the inspection is the date a Form FDA-483 listing the investigators' observations was issued. If no FDA Form-483 was issued, the date is the last day of the inspection.

3.       A Form FDA-483 is issued when investigators observe any significant objectionable conditions. It does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any relevant regulations. 

4.       This table reflects only FDA actions. It does not include State Board of Pharmacy actions, if any. To determine whether a registered outsourcing facility has been the subject of a state enforcement action, check with the State Board of Pharmacy for the state in which the facility is located. Some states post disciplinary or other actions on their web sites.

5.       "Closed" means the inspection has been closed without further action. "Open" means that FDA has not made a determination as to whether further action will be taken. If an action has been taken, it will be listed. Possible FDA actions include: warning letter; seizure; or injunction.

6.       The information in this column was provided by the registered outsourcing facility at the time of registration and has not been verified by FDA. “N/A”, indicates the registered outsourcing facility has not provided this information. In the future, FDA intends to provide information about whether the outsourcing facility also intends to compound nonsterile drugs from bulk drug substances. That information is not currently available to the Agency.

7.       This facility was the subject of at least one previous inspection relating to compounding that resulted in a Form 483, warning letter, or other action. For information about such inspections and resulting actions, see Compounding: Inspections, Recalls, and other Actions


Page Last Updated: 09/03/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.